Shareholders Equity (Quarterly) Chart

View Shareholders Equity (Quarterly) for INKT.
Upgrade now.
Sep '18
Jan '19
May '19
 
285.00
270.00
255.00
240.00
View Shareholders Equity (Quarterly) Chart
Start Trial

Historical Shareholders Equity (Quarterly) Data

View and export this data back to 2021. Start Trial.
Date Value
June 30, 2026 -14.03M
March 31, 2026 -12.69M
December 31, 2025 -14.23M
September 30, 2025 -13.51M
June 30, 2025 -25.19M
March 31, 2025 -21.79M
December 31, 2024 -19.59M
September 30, 2024 -17.55M
June 30, 2024 -16.58M
March 31, 2024 -20.30M
December 31, 2023 -18.06M
Date Value
September 30, 2023 -13.58M
June 30, 2023 -9.495M
March 31, 2023 -4.476M
December 31, 2022 -0.4013M
September 30, 2022 6.756M
June 30, 2022 13.69M
March 31, 2022 17.31M
December 31, 2021 23.78M
September 30, 2021 -76.51M
June 30, 2021 -63.18M

Shareholders' Equity Definition

Represents the value of Shareholders' Equity as of the close of the report date, belonging to both Preferred and Common Equity Shareholders.

Read full definition.

Shareholders Equity (Quarterly) Range, Past 5 Years

View Shareholders Equity (Quarterly) Range, Past 5 Years
Start Trial
--
Minimum
--
Maximum
--
Average
--
Median

Shareholders Equity (Quarterly) Benchmarks

View Shareholders Equity (Quarterly) Benchmarks
Start Trial
ACADIA Pharmaceuticals, Inc. 1.307B
Alnylam Pharmaceuticals, Inc. 1.354B
Anika Therapeutics, Inc. 137.28M
Savara, Inc. 143.66M
Vericel Corp. 370.04M

Shareholders Equity (Quarterly) Related Metrics